UK biotech investment faces structural headwinds. The market for IPOs remains weak, with AIM largely uncompetitive compared to NASDAQ, where biotech commands 70-80% of activity [#109]. Seed funding is particularly thin: £2 million rounds are rare in UK healthtech, whereas US investors routinely back companies at this level [#226]. One guest noted a "dearth of entrepreneurial energy" in the UK biotech sector, though this is slowly shifting [#304].
The constraints run deeper than capital scarcity. UK investors have few success stories in healthtech to point to, making it harder to justify backing new ventures. Angel investment itself contracted during the pandemic [#144]. Organisations like Parkinson's UK are trying to plug gaps with targeted funding (around £4 million annually), but acknowledge the sums are only barely sufficient to create critical mass [#160]. The underlying issue is not glamorous: venture capital itself was still a small and underdeveloped industry in Europe even into the mid-2000s [#273].
Search 450+ episodes and 42,000 chunks of healthtech conversation.